- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05683119
The Effect of Menstrual Cycle and Oral Contraceptive Pill Phase on Aspects of Exercise Physiology
The Effect of Menstrual Cycle and Oral Contraceptive Pill Phase on Aspects of Exercise Physiology and Athletic Performance in Female Athletes
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ashley Ambrose
- Phone Number: 87528 519-661-2111
- Email: ashley.ambrose@lhsc.on.ca
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A 3K7
- Recruiting
- Fowler Kennedy Sport Medicine Clinic
-
Contact:
- Kristen Reilly
- Phone Number: 86495 519-661-2111
- Email: kreill2@uwo.ca
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Cis gender women
- 18-40 years of age
- Body mass index ≥ 19.5 and ≤ 25 kg∙-2; an exception can be made in the case of some athletes where they have a higher BMI, but are considered more lean/muscular than fat.
- Must be defined as healthy, i.e., not having any medical condition or taking any medication known to affect any of the outcome measures. Examples include diagnosed hyperandrogenism from polycystic ovary syndrome, congenital adrenal hyperplasia, or other differences in sexual development.
- Cannot smoke
- Considered to be physically active. Participants training status will be classified using the criteria outlined by McKay et al. (In press). For this study, participants must be Tier 2 athletes or above (Table 1). In addition, participants will be considered on the basis of relative maximal oxygen consumption (Decroix et al., 2016); needing to be Performance Level 2 or above (Table 2). Participants must provide details on gravidity and parity and must not be in the postpartum period (i.e., within 12 months of childbirth), currently breastfeeding, or pregnant. Participants will be recruited based on their endogenous hormonal profile (i.e., eumenorrheic or OCP users) and these profiles (including inclusion/exclusion criteria) are described below in detail.
Group Specific Inclusion Criteria:
Group 1. Eumenorrheic [EUM]
- Must have menstrual cycle lengths ≥ 21 days and ≤ 35 days resulting in 9 or more consecutive periods per year
- Must provide evidence of a luteinising hormone (LH) surge
- Must demonstrate the required hormonal profile as defined in Table 3
- Cannot have used any type of hormonal contraceptives (HC) for a minimum of 3 months, but ideally 6 months, prior to enrolment
Group 2. Oral contraceptive pill [OCP] users
- Must have been taking their OCP ≥ 3 months prior to recruitment
- Must be taking a combined, monophasic, second generation OCP (see Table 4 for permitted brands)
- Must demonstrate the correct hormonal profile as defined in Table 5
Exclusion Criteria:
-Cannot speak, read and understand English
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: EUM Group
Participants must: have menstrual cycle lengths ≥ 21 days and ≤ 35 days resulting in 9 or more consecutive periods per year; provide evidence of a luteinising hormone (LH) surge; demonstrate the required hormonal profile as defined below; and have not used any type of hormonal contraceptives (HC) for a minimum of 3 months, but ideally 6 months, prior to enrolment. Phase 1- Indicated by the onset of bleeding until day 5 Oestrogen and progesterone levels are low Phase 2- Oestrogen higher than during phase 1 and 3 Progesterone higher than during phase 1, but lower than 6.36 nmol·L-1 Must be followed by a positive luteinising hormone surge Phase 3- +7 days after ovulation has been confirmed Oestrogen higher than phase 1, but lower than phase 2 Progesterone >16 nmol·L-1 |
This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle [MC] and oral contraceptive pill [OCP] use, on aspects of exercise physiology and athletic performance in female athletes.
This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes.
The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
|
|
Experimental: OCP Group
Participants must: have been taking their OCP ≥ 3 months prior to recruitment; be taking a combined, monophasic, second generation OCP; and demonstrate the correct hormonal profile as defined below. Pill-taking phase- Indicated by the 21 consecutive pill-taking days Oestrogen and progesterone levels are low; ≤ phase 1 of the menstrual cycle Pill-free phase- Indicated by the 7 consecutive pill-free days Oestrogen and progesterone levels may begin to rise in comparison with the pill-taking phase |
This project intends to investigate the effects of circulating fluctuations in oestradiol and progesterone, experienced during the menstrual cycle [MC] and oral contraceptive pill [OCP] use, on aspects of exercise physiology and athletic performance in female athletes.
This research aims to determine if a particular hormonal profile affects physiological functioning (e.g., muscle strength, maximum oxygen uptake) and/or athletic performance in female athletes.
The intervention will include a stretching regimen, balance test, push-ups, agility test, handgrip muscle test, vertical jump, flexibility test, cycling protocol, blood sample and height/ weight measurements.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Sample
Time Frame: Every visit (9-10 blood draws depending on the group). Through study completion, an average of 5 months.
|
A blood sample will be drawn by a trained phlebotomist from an antecubital vein.
Approximately 10 mL will be collected.
|
Every visit (9-10 blood draws depending on the group). Through study completion, an average of 5 months.
|
|
Cycling Protocol
Time Frame: Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
Prior to and following the cycling protocol a note will be made of any unique details of the test environment (i.e., temperature, humidity, pressure), performance, or athlete concerns in the comments section of the data sheet. Participants will complete a 5-minute warm-up at 35 W. Phase 1: The protocol will commence at a power output of 45 W and increased by 15 W every 4 min. For each stage, power output, average heart rate (HR) in the last 30 seconds, and blood lactate values in the last 15 seconds will be recorded. The last completed 4-minute workload will be recorded as maximal 4-minute power output. Phase 2: |
Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
|
Height
Time Frame: First visit only- Month 1
|
Height will be measured in bare feet, with minimal clothing, and no impeding hairstyles, using a stadiometer.
Participants will be positioned in the 'Frankfort Plane' and will be asked to take a deep breath, which they hold, while the measurement is taken.
|
First visit only- Month 1
|
|
Weight
Time Frame: Through study completion, an average of 5 months.
|
Body mass will be measured at every testing session by an experimenter using the same scales on each occasion (i.e., within and between participants) and the participants wearing minimal clothing and no shoes.
|
Through study completion, an average of 5 months.
|
|
Stork Balance Stand Test
Time Frame: Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
Participants are required to remove their shoes and place their hands on their hips, then position their non-supporting foot against the inside knee of the supporting leg. They will be given one minute to practice the balance. Participants must raise their heel to balance on the ball of their foot. The stopwatch is started as the heel is raised from the floor. The stopwatch is stopped if any of the follow occur:
|
Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
|
Muscular Endurance: Push-ups
Time Frame: Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
The push-up test is administered with participants starting in a modified knee push-up position (legs together, lower leg in contact with the mat and ankles plantar flexed, back straight, hands shoulder width apart, head up, using the knees as the pivotal point).
The participants must raise the body by straightening the elbows and return to the "down" position, until the chin touches the mat.
The stomach should not touch the mat.
The participant's back must be straight at all times and the participant must push up to a straight arm position.
The maximum number of push-ups performed consecutively without rest is counted as the score.
The test is stopped when the participant strains forcibly or unable to maintain the appropriate technique within two repetitions.
|
Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
|
Illinois Agility Test
Time Frame: Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
The length of the course is 10 meters and the width is 5 meters.
Four cones are used to mark the start, finish and the two turning points.
Another four cones are placed down the centre an equal distance apart.
Each cone in the centre is spaced 3.3 meters apart.
You will be asked to lie on your front (head to the start line) with your hands by your shoulders.
On the 'Go' command the stopwatch is started, and you must get up as quickly as possible and run around the course in the direction indicated, without knocking the cones over, to the finish line, at which the timing is stopped.
The total time in seconds is recorded.
The score is the best of three attempts.
Allow 1 minute rest between attempts.
Participants may continue to perform the test (beyond three attempts) as long as improvements are being made.
|
Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
|
Muscular Strength: Handgrip
Time Frame: Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
The participant holds the dynamometer in the dominant hand, with the arm at right angles and the elbow by the side of the body.
The handle of the dynamometer is adjusted if required - the base should rest on the first metacarpal (heel of palm), while the handle should rest on middle of the four fingers.
When ready the participant squeezes the dynamometer with maximum isometric effort, which is maintained for about 5 seconds.
No other body movement is allowed.
The participant should be strongly encouraged to give a maximum effort.
The score is the best of three attempts.
Allow 1 minute rest between attempts.
Participants may continue to perform the test (beyond three attempts) as long as improvements are being made.
|
Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
|
Countermovement (power) jump
Time Frame: Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
This test will be administered using the My Jump 2 app, which calculates the height, flight time, velocity, force, and power of vertical jumps by recording the jump and selecting accurately its take-off and landing.
All participants will follow the same jump protocol.
The participant squats down until the knees are bent at 90 degrees, then immediately jumps vertically as high as possible, landing back on the mat on both feet at the same time.
Allow one minute rest between trials.
The take-off must be from both feet, with no initial steps or shuffling.
The best result of three attempts is recorded - participants may continue to jump (beyond three attempts) as long as improvements are being made.
It is also important that the athlete not only jumps as high as possible, but also attempts to land in the same position as they took off - as jumping forwards, backwards or sideways can affect the test results.
|
Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
|
Sit and Reach Flexibility Test
Time Frame: Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
This test involves sitting on the floor with legs stretched out straight ahead.
Shoes should be removed.
The soles of the feet are placed flat against the box.
Both knees should be locked and pressed flat to the floor - the tester may assist by holding them down.
With the palms facing downwards, and the hands on top of each other or side by side, you must reach forward along the measuring line as far as possible.
Ensure that the hands remain at the same level, not one reaching further forward than the other.
After some practice reaches, you must reach out and hold that position for one-two seconds while the distance is recorded.
Make sure there are no jerky movements.
The score is the best of three attempts.
Allow 1 minute rest between attempts.
Participants may continue to perform the test (beyond three attempts) as long as improvements are being made.
|
Visits 2-9 (EUM Group) and Visits 3, 5, 7-10 (OCP Group). Through study completion, an average of 5 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Jane Thornton, Schulich-Family Medicine
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 120869
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menstrual Cycle
-
Taipei Medical University WanFang HospitalCompletedIrregular Menstrual Cycle | Regular Menstrual CycleTaiwan
-
University of British ColumbiaRecruiting
-
Riphah International UniversityRecruitingMenstrual CyclePakistan
-
Istanbul Medipol University HospitalRecruiting
-
Necmettin Erbakan UniversityNot yet recruitingMenstrual Cycle
-
Marmara UniversityCompleted
-
Fudan UniversityCompleted
-
University of BonnRadboud University Medical Center; University Hospital, BonnRecruiting
-
University of British ColumbiaCompleted
-
University of ArizonaCompletedMenstrual CycleUnited States
Clinical Trials on Exercise and blood draw
-
Memorial Sloan Kettering Cancer CenterUniversity of California, Los Angeles; Weill Medical College of Cornell UniversityActive, not recruiting
-
Abbott Point of CareCompletedPrecision of Potassium (K) Test in Capillary Whole BloodUnited States, Canada
-
Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Vanderbilt-Ingram Cancer CenterWren Laboratories LLCCompletedMelanomaUnited States
-
Turtle Health, Inc.Completed
-
University Hospital, Strasbourg, FranceNot yet recruitingKidney Transplantation | Humoral Rejection | Kidney Allograft Biopsy | Microvascular Inflammation
-
Assistance Publique Hopitaux De MarseilleUnknownSubarachnoid Hemorrhage (SAH) From Ruptured AneurysmFrance
-
Mayo ClinicCompleted
-
Memorial Sloan Kettering Cancer CenterYale University; University of New MexicoCompleted